AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and ...

This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

The AstraZeneca PLC ADR AZN slipped 1.58% to $77.14 Monday, on what proved to be an all-around great trading session for the ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...

According to GLOBOCAN 2022 data, lung cancer remains the fourth most common cause of cancer-related mortality in India.